

COVID-19 is an emerging, rapidly evolving situation.

▼
Expand for resources



NATIONAL CANCER INSTITUTE

Surveillance, Epidemiology, and End Results Program

Browse the SEER Cancer Statistics Review 1975-2017

(<https://seer.cancer.gov>)

The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

1. First select the CSR Section, then a Table/Figure from that section.
2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (https://seer.cancer.gov/csr/1975_2017/results_figure/sect_01_intro1_7pgs.pdf) (PDF, 528 KB) and Technical Notes (https://seer.cancer.gov/csr/1975_2017/results_figure/sect_01_intro2_25pgs.pdf) (PDF, 794 KB) pages.

Section:

- Lung and Bronchus



Table/Figure:

Table 15.28: Case Distribution by Histology, Both Sexes



Submit

Download and Print: **Download Printer-friendly PDF** (https://seer.cancer.gov/results_single/sect_15_table.28.pdf)
Download data (https://seer.cancer.gov/download_csr_datafile.php/sect_15_table.28.csv)

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

**Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Both Sexes by Race**

Histology ^a	All Races	White	Black	Asian/ Pacific Islander	American Indian /Alaska Native ^b	Hispanic
------------------------	-----------	-------	-------	----------------------------	---	----------

Histology ^a	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count
Carcinoma	47.8	319,082	99.8%	261,850	99.8%	34,890	99.8%	19,767	99.8%	1,089	99.8%	19,717
Small cell (8002,8041-8045)	5.9	39,968	12.5%	34,951	13.3%	3,409	9.7%	1,335	6.7%	153	14.0%	2,029
Non-small cell	40.5	269,735	84.3%	219,330	83.6%	30,289	86.6%	17,918	90.4%	886	81.2%	17,018
Squamous and transitional cell ^d	10.9	72,205	22.6%	60,448	23.0%	8,247	23.6%	2,876	14.5%	326	29.9%	3,818
Adenocarcinoma ^e	24.1	161,224	50.4%	128,729	49.0%	17,900	51.2%	13,318	67.2%	450	41.2%	10,664
Large cell ^f	0.6	4,150	1.3%	3,361	1.3%	583	1.7%	183	0.9%	-	-	226
Non-small cell carcinoma ^g	2.2	14,719	4.6%	11,919	4.5%	1,909	5.5%	765	3.9%	56	5.1%	929
Other specified carcinomas ^h	2.6	17,437	5.5%	14,873	5.7%	1,650	4.7%	776	3.9%	46	4.2%	1,381
Carcinoma, NOS ⁱ	1.4	9,379	2.9%	7,569	2.9%	1,192	3.4%	514	2.6%	50	4.6%	670
Sarcoma ^j	0.1	496	0.2%	413	0.2%	47	0.1%	30	0.2%	-	-	68
Other specified types ^k	0.0	269	0.1%	217	0.1%	34	0.1%	16	0.1%	-	-	28
Total	47.9	319,847	100.0%	262,480	100.0%	34,971	100.0%	19,813	100.0%	1,091	100.0%	19,813

Footnotes:

Source: (<https://seer.cancer.gov>) SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts). Percents may not sum to 100 due to rounding.

^a (<https://seer.cancer.gov>) Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b (<https://seer.cancer.gov>) Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c (<https://seer.cancer.gov>) Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d (<https://seer.cancer.gov>) Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e (<https://seer.cancer.gov>) Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f (<https://seer.cancer.gov>) Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g (<https://seer.cancer.gov>) Non-small cell carcinoma includes histology 8046.

^h (<https://seer.cancer.gov>) Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ (<https://seer.cancer.gov>) Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j (<https://seer.cancer.gov>) Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k (<https://seer.cancer.gov>) Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: (<https://seer.cancer.gov>) For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- (<https://seer.cancer.gov>) Statistic not shown due to fewer than 16 cases during the time period.

Page Navigation: << Previous ([https://seer.cancer.gov/csr/1975_2017/browse_csr.php?](https://seer.cancer.gov/csr/1975_2017/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.27)

sectionSEL=15&pageSEL=sect_15_table.27) **Next >>** ([https://seer.cancer.gov/csr/1975_2017/browse_csr.php?](https://seer.cancer.gov/csr/1975_2017/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.29)

sectionSEL=15&pageSEL=sect_15_table.29)
